- Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of STX-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
STX-100 (anti-alpha v beta 6 monoclonal antibody) versus Placebo in Patients with
Idiopathic Pulmonary Fibrosis.
Are you male or female between the ages of 18 and 84
Have you been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)
About the study
You may be eligible for a research study, to find out if STX-100 is safe to take without
causing too many side effects, and to look at how your body reacts to STX-100.
Participants will sign an informed consent prior to screening for eligibility
Participants entering the study will receive an injection in the arm of STX-100 or
Placebo (normal saline) once weekly for 8 doses (7 weeks)
Participants will be required to have a procedure done twice to collect fluid from
their lungs
Participants will take part in the study for approximately 5 ½ months.
You will be compensated up to $2, 325.00 for your time.
For more information, please contact:
Margaret Hegarty, R.N. at 617-724-7318
Institution: Massachusetts General Hospital (MGH), Boston, MA
Principal Investigator: Leo C. Ginns, M.D.
Co-Investigator: Colleen Channick, M.D.
Co-Investigator: Fiona Gibbons, M.D.
Co-Investigator: David Kanarek, M.D.
Co-Investigator: Andrew Tager, M.D.
Enrollment Information:
For further information about enrolling a patient in this trial, contact the person below.
Name: Margaret Hegarty, R.N.
Email: mhegarty@partners.org
Phone: 617-724-7318
Idiopathic Pulmonary Fibrosis.
Are you male or female between the ages of 18 and 84
Have you been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)
About the study
You may be eligible for a research study, to find out if STX-100 is safe to take without
causing too many side effects, and to look at how your body reacts to STX-100.
Participants will sign an informed consent prior to screening for eligibility
Participants entering the study will receive an injection in the arm of STX-100 or
Placebo (normal saline) once weekly for 8 doses (7 weeks)
Participants will be required to have a procedure done twice to collect fluid from
their lungs
Participants will take part in the study for approximately 5 ½ months.
You will be compensated up to $2, 325.00 for your time.
For more information, please contact:
Margaret Hegarty, R.N. at 617-724-7318
Institution: Massachusetts General Hospital (MGH), Boston, MA
Principal Investigator: Leo C. Ginns, M.D.
Co-Investigator: Colleen Channick, M.D.
Co-Investigator: Fiona Gibbons, M.D.
Co-Investigator: David Kanarek, M.D.
Co-Investigator: Andrew Tager, M.D.
Enrollment Information:
For further information about enrolling a patient in this trial, contact the person below.
Name: Margaret Hegarty, R.N.
Email: mhegarty@partners.org
Phone: 617-724-7318
Institution – MGH - Massachusetts General Hospital, Boston, MA
Principal Investigator – Leo C Ginns, MD
Enrollment Information
For further information about enrolling a patient in this trial, contact the person below.
Name – Margaret T Hegarty, RN
Email – mhegarty@partners.org
Phone – 617-724-7318
